STOCK TITAN

Turn Therapeutics (TTRX) DEF 14A Filings

TTRX NASDAQ

Here are the DEF 14A proxy statements from Turn Therapeutics Inc. (TTRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TTRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TTRX filings page.

Rhea-AI Summary

Turn Therapeutics Inc. (TTRX) will hold its virtual 2026 annual meeting on November 30, 2026, at 12:00 p.m. Eastern Time. Shareholders will vote on electing Bradley Burnam, Chief Executive Officer, and Dr. Neil Ghodadra, Chief Medical Officer, to two Class I director seats through the 2029 annual meeting, and on ratifying WithumSmith+Brown, PC as the independent registered public accounting firm for fiscal 2026. The board recommends voting FOR both nominees and the auditor ratification.

As of October 5, 2026, 30,532,704 common shares were issued and outstanding. The ownership table reports 18,297,940 shares, or 55.89%, beneficially owned by all directors and executive officers as a group; it lists Bradley Burnam at 15,116,260 shares, or 49.51%. Withum has served since April 1, 2025, and its reported 2025 audit fees were $351,000, including fees related to the 2023 and 2024 audits performed during 2025 and 2025 quarterly reviews. Four non-employee directors each received 10,000 restricted stock units in 2025, scheduled to vest in full on October 8, 2026, subject to continued service.